Bioanalytical Method Comparison Strategy for Clinical Anti-drug Antibody Immunoassays.

Area of Science:

• Bioanalytical Method Development
• Immunogenicity Assessment
• Pharmaceutical Development

Background:

• FDA guidance mandates method comparability for anti-drug antibody (ADA) assays run across multiple labs.
• Ensuring assay consistency is crucial for reliable immunogenicity data in drug development.

Purpose of the Study:

• To evaluate a risk-based comparability approach for ADA assays, integrating technical and clinical aspects.
• To establish robust criteria for method comparability between independent laboratories.

Main Methods:

• Technical comparability assessed using Two One-Sided T-tests (TOST) on relative sensitivity (RS) means.
• Clinical comparability evaluated based on molecule immunogenicity risk (basic/in-depth assessments).
• Basic assessment criteria: ≥80% negative, ≥90% low positive, 100% high positive detection.
• In-depth assessment uses Cohen's Kappa score (>0.40) on incurred samples.

Main Results:

• The proposed strategy provides a framework for robust technical and clinical method comparability.
• Specific performance criteria were defined for basic and in-depth clinical assessments.
• Statistical methods like TOST and Cohen's Kappa enable quantitative comparability evaluation.

Conclusions:

• The risk-based approach effectively addresses technical and clinical aspects of ADA assay comparability.
• This strategy ensures reliable immunogenicity data, even with limited incurred samples.
• The methodology supports regulatory compliance and consistent drug development outcomes.